Sentiment Trading

BioMarin Pharmaceutical Inc. has acquired Inozyme Pharma Inc. for $270 million, expanding its enzyme therapy business and rare disease portfolio, but the deal has raised concerns about Inozyme’s financial health and potential legal challenges.

BioMarin Pharmaceutical Inc. has acquired Inozyme Pharma, Inc. for $270 million, expanding its enzyme therapy business and gaining access to Inozyme’s innovative treatments for rare diseases.